STEP-HFpEF: Semaglutide reduces heart failure symptoms and body weight in HFpEF patients at one year
Key Points: More than 80% of patients with HFpEF are overweight or obese, but there has not yet been a study examining the use of weight-loss agents in body weight…
COP-AF: Colchicine did not reduce AF or myocardial injury after non-cardiac surgery, but post-hoc analysis suggest benefit in composite outcomes
Key Points This trial randomizing patients aged 55 or older to colchicine or placebo following non-cardiac thoracic surgery found no difference in the co-primary endpoints of atrial fibrillation or myocardial…
NOAH-AFNET 6: No benefit of oral anticoagulation among patients with atrial high-rate episodes in the absence of confirmed AF
Key Points This trial randomized elderly patients without a known diagnosis of atrial fibrillation with device-detected atrial high-rate episodes (AHREs) and a median CHA2DS2VASC of 4 to edoxaban or placebo.…
HOST-IDEA: 3-Month DAPT Noninferior to 12-Month DAPT in Patients Undergoing PCI using third-generation stents
Key Points: Among patients undergoing PCI using third-generation DES with ultrathin struts and advanced polymer technology, 3- to 6-month DAPT was noninferior to 12-month DAPT for net adverse clinical events…
UK Biobank Analysis: Self-reported LCHF Diet May be Linked to Cardiac Events
Key Points: In spite of the increase popularity of low-carbohydrate high-fat diet due to purported benefit in a variety of conditions, there is limited data on the effect of LCHF…
hsCRP is a Stronger Predictor of CV Events and Death than LDL-C in High-Risk Patients on Statins
Key Points: Both inflammatory risk and hyperlipidemia and crucial risk factors for MACE in patients at high risk of CVD. In a large collaborative study of patients combining data from…
FREEDOM COVID: Therapeutic dose anticoagulation does not reduce MACE in non-critically ill COVID-19 patients
Key Points: There have been conflicting data on the role and recommended dosage of anticoagulation in non-critically-ill patients with COVID-19. In the open-label FREEDOM COVID study, therapeutic anticoagulation was compared…
STELLAR: Sotatercept improves 6MWD in PAH patients and WHO FC II-III
Key Points: Sotatercept is a novel activin signaling inhibitor which was designed to target pulmonary vascular remodeling in PAH. In the STELLAR study, sotatercept was tested against placebo on a…
Dapagliflozin Reduces PCWP at Rest and Exercise, Plasma Volume, and Weight in HFpEF patients
Key Points: SGLT2i therapy reduces HF hospitalizations and CV mortality in HFpEF, but the mechanism is not yet clear. In this single-center, double-blinded RCT, patients with HFpEF were randomized to…
BMAD Trial: Use of data from μCor, A Novel Wearable Sensor, reduces HF readmissions following a recent HF hospitalization
Key Points: The μCor monitor is a novel device that uses radiofrequency signals to assess the wearer's thoracic fluid index, which can indicate HF complications. The BMAD trial enrolled…
A Novel, Oral, PSCK-9 Inhibitor Showed Significant and Dose-dependent Reduction of LDL compared to Placebo
Key Points -Lowering LDL-C is known to reduce the risk of ASCVD -In patients at very high risk for ASCVD or in those with intolerance to statins, PCSK-9 inhibitors are…
LIVE HCM Trial: Vigorous Exercise in Patients with HCM Not Associated with Increased Risk of Adverse Cardiac Events
Key Points -HCM is the most common cause of sudden cardiac death in athletes -In patient diagnosed with HCM, long-established guidelines have advocated against vigorous exercise with the assumption this…
The future is now: A wrist-worn Sensor Coupled with AI Accurately Predicts Troponin Elevation in ACS Patients
Key Points - Prompt identification of patients suffering from ACS requires measurements of the blood level of the cardiac troponin biomarker, which is traditionally dependent on laboratory turn-around times. -…
Low Cardiac Risk for Elite Level Athletes With Genetic Heart Disease
Key Points -Patients with diagnosed sudden cardiac death (SCD)-predisposing genetic heart diseases (GHDs) have traditionally been restricted from participating in competitive sporting activities. -This retrospective study was the first to…
Macitentan/Tadalafil Fixed Dose Combination reduces PVR compared with monotherapy
Key Points: Macitentan and Tadalfil are frequently used in combination for PAH, which opens up the possibility of a fixed-dose combination pill. In the DUE study, macitentan/tadalafil FDC therapy was…
A Virtual Care Team-Guided Strategy Improved GDMT in Hospitalized HFrEF Patients: the IMPLEMENT-HF Study
Key Points Despite an extensive body of evidence supporting the benefit and use of guideline-directed medical therapy (GDMT) for patients with heart failure with reduced ejection fraction (HFrEF), its implementation…
Lifelong Endurance Not linked to Favorable Coronary Plaque Composition but Less Vulnerable ones: MASTER at HEART Trial
Key Points Cardiovascular risk mitigation strategies such as the recommendation to engage in a more active lifestyle are common in primary care and cardiovascular clinics, yet more nuanced data gauging…
Treat-to-target LDL Strategy Non-inferior to High-Intensity Statin Therapy In CAD Patients: the LODESTAR trial
Key Points Appropriate lipid management is of critical importance in preventing further cardiac events in patients with atherosclerotic cardiovascular disease, yet different approaches exist to achieving lipid control In this…
Black women with TTR V122I variant have higher risk of CVD and all-cause mortality
Key Points: The prognostic significance of the V122I variant (associated with wt-ATTR) in Black women has not yet been established. A substudy of the WHI aimed to establish…
The Final Word on Transcatheter edge-to-edge Repair with MitraClip– COAPT Five Year Results
Key Points: Two-year results showed improved outcomes with the MitraClip device but long-term results had not been reported; TEER was allowed in the control arm only after the 2-year primary…